ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 577,99
-0,72%
Dow Jones
40 211,72
0,53%
DAX
18 514,93
-0,46%
Brent Oil
83,555
-0,93%
Bitcoin
63 333,88
-2,34%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Intellia Therapeutics Inc (NTLA)

  7. Intellia Therapeutics Inc (NTLA) Actualités

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateHeureSourceTitreSymboleSociété
05/01/202218h05TipRanksIntellia Therapeutics (NTLA) Receives a Buy from H.C. WainwrightNASDAQ:NTLAIntellia Therapeutics Inc
05/01/202213h30GlobeNewswire Inc.Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune DiseasesNASDAQ:NTLAIntellia Therapeutics Inc
29/12/202122h21Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:NTLAIntellia Therapeutics Inc
20/12/202113h30GlobeNewswire Inc.Intellia Therapeutics Appoints Derek Hicks as Chief Business OfficerNASDAQ:NTLAIntellia Therapeutics Inc
13/12/202113h30GlobeNewswire Inc.Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
26/11/202121h25Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NTLAIntellia Therapeutics Inc
22/11/202113h30GlobeNewswire Inc.Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)NASDAQ:NTLAIntellia Therapeutics Inc
10/11/202100h11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
05/11/202112h30GlobeNewswire Inc.Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual MeetingNASDAQ:NTLAIntellia Therapeutics Inc
04/11/202112h42Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NTLAIntellia Therapeutics Inc
04/11/202112h30GlobeNewswire Inc.Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
28/10/202113h30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
21/10/202114h13Dow Jones NewsIntellia Gets FDA Orphan Designation for NTLA-2001 in ATTR AmyloidosisNASDAQ:NTLAIntellia Therapeutics Inc
21/10/202113h30GlobeNewswire Inc.Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) AmyloidosisNASDAQ:NTLAIntellia Therapeutics Inc
20/10/202113h30GlobeNewswire Inc.Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual CongressNASDAQ:NTLAIntellia Therapeutics Inc
13/10/202113h01GlobeNewswire Inc.Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 TechnologyNASDAQ:NTLAIntellia Therapeutics Inc
12/10/202113h30GlobeNewswire Inc.Intellia Therapeutics to Present New Preclinical Data Highlighting In Vivo and Ex Vivo Genome Editing Advances at 2021 European Society of Gene & Cell Therapy Annual CongressNASDAQ:NTLAIntellia Therapeutics Inc
06/10/202113h30GlobeNewswire Inc.Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
27/09/202113h30GlobeNewswire Inc.Intellia Therapeutics to Present at Chardan’s 5th Annual Genetic Medicines ConferenceNASDAQ:NTLAIntellia Therapeutics Inc
26/09/202115h27TipRanksNTLA Stock Getting Ahead in Gene Editing RaceNASDAQ:NTLAIntellia Therapeutics Inc
16/09/202114h16Dow Jones NewsIntellia: FDA Accepts NTLA-5001 IND in Acute Myeloid LeukemiaNASDAQ:NTLAIntellia Therapeutics Inc
16/09/202113h30GlobeNewswire Inc.Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid LeukemiaNASDAQ:NTLAIntellia Therapeutics Inc
31/08/202113h30GlobeNewswire Inc.Intellia Therapeutics to Present at September Healthcare Investor ConferencesNASDAQ:NTLAIntellia Therapeutics Inc
05/08/202122h48Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NTLAIntellia Therapeutics Inc
05/08/202113h30GlobeNewswire Inc.Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
29/07/202113h30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
05/07/202117h00TipRanksIntellia Therapeutics Closes Stock Offering of $690MNASDAQ:NTLAIntellia Therapeutics Inc
02/07/202122h01GlobeNewswire Inc.Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common StockNASDAQ:NTLAIntellia Therapeutics Inc
01/07/202122h56Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:NTLAIntellia Therapeutics Inc
30/06/202103h08GlobeNewswire Inc.Intellia Therapeutics Announces Pricing of Public Offering of Common StockNASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA

Dernières Valeurs Consultées

EU
PX1
CAC 40
NASDAQ
AAPL
Apple
EU
CAP
Capgemini
EU
CS
Axa
EU
BNP
BNP Paribas
EU
AI
Air Liquide
NASDAQ
AMZN
Amazon.com
NYSE
DIS
Walt Disney
NASDAQ
MSFT
Microsoft
EU
ACA
Credit Agricole
EU
VIV
Vivendi
EU
ORA
Orange
EU
RI
Pernod Ricard
COIN
ETHUSD
Ethereum
EU
ML
Michelin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés